Halozyme Therapeutics, Inc. (NASDAQ:HALO) is set to announce third quarter earning results on Monday 2nd November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, HALO to report 3Q20 income of $ 0.19 per share.
For the full year, analysts anticipate top line of $ 235.94 million, while looking forward to income of $ 0.69 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 230.00 million ~ $ 245.00 million, where as bottomline are predicted in a range of $ 0.60 ~ $ 0.75 per share
Click Here For More Historical Outlooks Of Halozyme Therapeutics, Inc.
Previous Quarter Performance
Halozyme Therapeutics, Inc. revealed income for the second quarter of $ 0.19 per share, from the revenue of $ 55.22 million. The quarterly revenues expanded 29.75 percent compared with the same quarter last year. Wall street analysts are predicting, HALO to report 2Q20 income of $ 0.25 per share from revenue of $ 66.68 million. The bottom line results missed street analysts by $ 0.06 or 24 percent, at the same time, top line results fell short of analysts by $ 11.46 million or 17.19 percent.
Stock Performance
On Friday, shares of Halozyme Therapeutics, Inc. has traded high as $ 28.86 and has cracked $ 27.71 on the downward trend, reaching $ 28.00 with volume of 1.16 million shares.
According to the previous trading day, closing price of $ 28.00, representing a 127.30 % increase from the 52 week low of $ 12.71 and a 8.69 % decrease over the 52 week high of $ 31.64.
The company has a market capital of $ 3.84 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Halozyme Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.halozyme.com
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The companys products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.